Senseonics shares rise 14% after Q3 revenue reaches $19.6 million, beating estimates, as 2026 revenue guidance climbs to $68 million-$70 million.
Senseonics Holdings (AMEX:SENS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.
Senseonics's Eversense 365 CGM drives sales and margin gains, but adoption, funding, dilution, and valuation risks remain. Click here for more on SENS stock.
BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
(Updates with the latest stock price in the headline and last paragraph.) Beta Bionics (BBNX) rep
Beta Bionics (BBNX) said Tuesday it partnered with Senseonics (SENS) to integrate its iLet Bionic Pa
IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system. Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics exp
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable sens
Senseonics (SENS) has partnered with Beta Bionics (BBNX) to integrate its Eversense 365 continuous g
GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences. Details on the Company’s participation appear below: Lake Street 10th Annual Big Ideas Growth Conference – September 10, 2026 (New York, NY)Management will host o
This is the newest page. Registered accounts read further back.